| Preventing coronary artery disease in the West of Scotland: implications for primary prevention. | |
| | |
MedLine Citation:
|
PMID: 9860377 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The effectiveness of plasma cholesterol reduction therapy is no longer in question. Recent studies of cholesterol-lowering drug therapy demonstrate significant reductions in risks of mortality and coronary events in patients with existing coronary artery disease. The West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated the therapy's effectiveness as primary prevention in patients without demonstrated coronary artery disease. Now that the efficacy of lipid reduction has been demonstrated conclusively, we face the difficult question of deciding what the treatment goals should be, whom to treat, and how to make those decisions cost effectively. These questions have complex social and ethical components and will lead to considerable discussion about how lipid-decreasing drugs will be used. |
| | |
Authors:
|
J Shepherd |
Related Documents
:
|
9386157 - Association between serum amyloid a proteins and coronary artery disease: evidence from... 3059787 - Review of major intervention studies in hypertension and hyperlipidemia: focus on coron... 19816987 - Statins as anti-arrhythmics: a systematic review part ii: effects on risk of ventricula... 16061117 - Preoperative statin use and outcomes following cardiac surgery. 1721127 - Repetitive nonsustained monomorphic ventricular tachycardia aborted by methoxamine and ... 2862707 - Angina after aortocoronary bypass grafting: combined medical therapy including nifedipine. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The American journal of cardiology Volume: 82 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1998 Nov |
Date Detail:
|
Created Date: 1999-01-06 Completed Date: 1999-01-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 57T-59T Citation Subset: AIM; IM |
Affiliation:
|
Department of Pathological Biochemistry, University of Glasgow, Scotland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
economics,
therapeutic use* Cholesterol, LDL / blood Coronary Disease / economics, mortality, prevention & control* Double-Blind Method Female Follow-Up Studies Humans Hypercholesterolemia / drug therapy* Male Middle Aged Pravastatin / economics, therapeutic use* Primary Prevention / economics Randomized Controlled Trials as Topic Scotland |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 81093-37-0/Pravastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Coronary artery disease: the Scandinavian Simvastatin Survival Study experience.
Next Document: The new pathophysiology of coronary artery disease.